Company intelligence / Profile preview
MicroVAX
Manassas, Virginia, United Statesmicrovax2.org ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
MicroVAX’s lead program—a recombinant adenoviral vector vaccine encoding a fusion of MUC1 and CD40L—has completed preclinical studies showing potent immune activation and tumor regression. The first-in-human Phase 1 trial began in Singapore in patients with relapsed/refractory epithelial cancers. Early results indicate good tolerability and immune response induction; enrollment was ongoing as of the last update[7].
- Therapeutic areas
- Infectious DiseasesOncology
- Modalities
- VaccineRecombinant fusion proteinAdenoviral vector
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Singapore Clinical Research Institute (SCRI)National Cancer Centre Singapore (NCCS)
Beyond the preview
Go deeper on MicroVAX.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MicroVAX.